PATIENTS WHO HAVE MBC WITH VISCERAL AND MULTIPLE METASTASES OFTEN HAVE LESS FAVORABLE OUTCOMES

There is lower median survival time for patients who develop visceral metastases vs nonvisceral metastases3a
Nonvisceral (23.2 months) vs visceral (10.9 months) metastatic breast cancer (MBC) median survival comparison from a retrospective analysis - chart Nonvisceral (23.2 months) vs visceral (10.9 months) metastatic breast cancer (MBC) median survival comparison from a retrospective analysis - chart
  • A retrospective database analysis of 111 women at a single center in Canada between 2005-2007 found that about 67%-73% of patients with metastatic breast cancer developed visceral metastases.17 A retrospective analysis of 6 clinical studies between 1983-2001 (N=640) found that in 57%-74% of patients, visceral metastases developed as the dominant metastatic site7
  • Further studies demonstrate that up to 85% of patients will develop visceral metastases at some point in the course of their disease5,18-20
  • Visceral metastases are associated with more aggressive metastatic breast cancer compared with nonvisceral metastases; patients tend to have worse outcomes3
The number of metastatic sites is associated with more aggressive MBCa
  • The presence of multiple metastatic lesions or sites is associated with poor prognosis in patients with metastatic breast cancer4
  • Patients with metastatic breast cancer who present metastases at ≥3 sites are likely to have a comparatively less favorable outcome than those with ≤2 metastatic sites6
  • a Univariate survival analysis from a retrospective database of 346 patients diagnosed with metastatic breast cancer after first recurrence between 1970 and 1991. All patients had undergone surgery for primary breast cancer and may have received radiation, hormonal therapy, and/or chemotherapy for metastatic disease.3
  • More Detail on Multiple Metastases

    THERE IS LOWER MEDIAN SURVIVAL TIME FOR PATIENTS WITH INCREASING NUMBER OF METASTATIC SITES4a

    MBC median survival comparison: 3 or more metastatic sites: median survival of 19.3 months, 2 metastatic sites: median survival of 24.5 months, 1 metastatic site: median survival of 31.3 months - chartMBC median survival comparison: 3 or more metastatic sites: median survival of 19.3 months, 2 metastatic sites: median survival of 24.5 months, 1 metastatic site: median survival of 31.3 months - chart
    • aUnivariate survival analysis of 1430 patients from 8 consecutive prospective trials conducted between 1977 and 1992 of anthracycline-based first-line chemotherapy in metastatic breast cancer.
    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL